| Kathryn Verlinghieri, CRNP | |
|
130 S Bryn Mawr Ave, Suite H321, Bryn Mawr, PA 19010-3121 | |
| (484) 337-4097 | |
| (484) 337-4082 |
| Full Name | Kathryn Verlinghieri |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Adult Health |
| Location | 130 S Bryn Mawr Ave, Bryn Mawr, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073908406 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | SP014622 (Pennsylvania) | Primary |
| Entity Name | Main Line Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922077643 PECOS PAC ID: 1951215201 Enrollment ID: O20040308000373 |
News Archive
Surgeons make optimal use of all their senses to master difficult operations. When visibility is poor, they locate anatomy by palpation or they hear the optimal moment to stop drilling.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem's Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.
SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).
Researchers have discovered how the protein Hap1, which is abundant in the brain's hypothalamus, serves as the link between circulating insulin in the blood and the neural circuitry that controls feeding behavior in mice.
Genesys Health System has agreed to pay the United States $669,413 to settle a lawsuit alleging that the health care provider violated the False Claims Act by submitting false claims to Medicare, the Justice Department announced today.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Verlinghieri, CRNP 130 S Bryn Mawr Ave, Suite H321, Bryn Mawr, PA 19010-3121 Ph: (484) 337-4097 | Kathryn Verlinghieri, CRNP 130 S Bryn Mawr Ave, Suite H321, Bryn Mawr, PA 19010-3121 Ph: (484) 337-4097 |
News Archive
Surgeons make optimal use of all their senses to master difficult operations. When visibility is poor, they locate anatomy by palpation or they hear the optimal moment to stop drilling.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem's Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.
SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).
Researchers have discovered how the protein Hap1, which is abundant in the brain's hypothalamus, serves as the link between circulating insulin in the blood and the neural circuitry that controls feeding behavior in mice.
Genesys Health System has agreed to pay the United States $669,413 to settle a lawsuit alleging that the health care provider violated the False Claims Act by submitting false claims to Medicare, the Justice Department announced today.
› Verified 2 days ago
Mrs. Jodi Lynn Kanzinger, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 130 S Bryn Mawr Ave, Suite H321, Bryn Mawr, PA 19010 Phone: 484-337-4097 Fax: 484-337-4086 | |
Harriet Marie Mccarney, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1030 E Lancaster Ave, Bryn Mawr, PA 19010 Phone: 610-525-3225 Fax: 610-525-4932 | |
Jenna Walck, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr, PA 19010 Phone: 484-337-3000 | |
Stephanie Nicole Libes, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr, PA 19010 Phone: 215-662-3743 Fax: 215-349-5895 | |
Ms. Meghan R. Skakun, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr Hospital, Bryn Mawr, PA 19010 Phone: 484-337-4618 Fax: 484-337-4661 | |
Awilda Rodriguez, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 830 Old Lancaster Rd Ste 206, Bryn Mawr, PA 19010 Phone: 484-380-3094 | |
Rachel Melissa Goldstein, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 918 County Line Rd, Bryn Mawr, PA 19010 Phone: 610-525-6086 |